355 results on '"respiratory viral infections"'
Search Results
2. Changes in seasonal respiratory viral infections among pediatric population around the COVID-19 pandemic; 2019–2023.
- Author
-
Alzaydi, Mashael, Alosaimi, Aeshah, Alghamdi, Atheer A., Bamogaddam, Israa Y., Altassan, Maryam A., Almazrua, Afnan, Althawadi, Sahar, and Alghamdi, Salem M.
- Subjects
- *
VIRUS diseases , *COVID-19 pandemic , *CHILD patients , *RESPIRATORY infections , *PANDEMIC preparedness - Abstract
Purpose: This study aims to describe the prevalence and the fluctuations of respiratory viral infections among the pediatric population in a tertiary care center during 2019–2023, parallel with the COVID-19 pandemic, and the specific preventative measures applied in the region during this time. Methods: In this observational study, we extracted all respiratory virus PCR tests collected from pediatric patients (< 15 years old) between January 2019 and March 2023. Data on the positivity rate and prevalence of 18 respiratory viruses were presented over the study period. Results: The lowest rate for the studied respiratory viruses was observed in 2020/2021 (during the COVID-19 pandemic), followed by a gradual increase in positive cases in the 2021/2022 season. Timing (seasonality) was altered during 2022/2023 with an early circulation of respiratory viruses in May-June followed by an early start of the usual respiratory viruses' season in September, leading to prolonged respiratory virus activity. Most respiratory viruses were circulating at unprecedented levels during the 2022/2023 season, with rhinovirus/enterovirus being the most commonly detected virus in all seasons. Other viruses that had atypical activity after the COVID-19 pandemic were influenza A(H3) virus, adenovirus, and parainfluenza 3 virus. Conclusion: Our study demonstrates the extended influence of the COVID-19 pandemic and its associated community restriction measures on the timing and distribution of other respiratory viruses. Continuous monitoring of changes in the circulation of respiratory viruses is crucial for the success of related public health measures such as vaccination distributions and epidemic preparedness. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Neurological Impact of Respiratory Viruses: Insights into Glial Cell Responses in the Central Nervous System.
- Author
-
Mora, Valentina P., Kalergis, Alexis M., and Bohmwald, Karen
- Subjects
RESPIRATORY syncytial virus ,NEUROGLIA ,VIRUS diseases ,CENTRAL nervous system ,MICROGLIA ,SARS-CoV-2 - Abstract
Respiratory viral infections pose a significant public health threat, particularly in children and older adults, with high mortality rates. Some of these pathogens are the human respiratory syncytial virus (hRSV), severe acute respiratory coronavirus-2 (SARS-CoV-2), influenza viruses (IV), human parvovirus B19 (B19V), and human bocavirus 1 (HBoV1). These viruses cause various respiratory symptoms, including cough, fever, bronchiolitis, and pneumonia. Notably, these viruses can also impact the central nervous system (CNS), leading to acute manifestations such as seizures, encephalopathies, encephalitis, neurological sequelae, and long-term complications. The precise mechanisms by which these viruses affect the CNS are not fully understood. Glial cells, specifically microglia and astrocytes within the CNS, play pivotal roles in maintaining brain homeostasis and regulating immune responses. Exploring how these cells interact with viral pathogens, such as hRSV, SARS-CoV-2, IVs, B19V, and HBoV1, offers crucial insights into the significant impact of respiratory viruses on the CNS. This review article examines hRSV, SARS-CoV-2, IV, B19V, and HBoV1 interactions with microglia and astrocytes, shedding light on potential neurological consequences. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Targeting host-virus interactions: in silico analysis of the binding of human milk oligosaccharides to viral proteins involved in respiratory infections
- Author
-
Anees Ahmed Mahaboob Ali, Adarsh Vishal, and Everette Jacob Remington Nelson
- Subjects
Human milk oligosaccharides ,Respiratory viral infections ,Host-virus interactions ,Molecular docking ,MD simulations ,Antiviral therapy ,Medicine ,Science - Abstract
Abstract Respiratory viral infections, a major public health concern, necessitate continuous development of novel antiviral strategies, particularly in the face of emerging and re-emerging pathogens. In this study, we explored the potential of human milk oligosaccharides (HMOs) as broad-spectrum antiviral agents against key respiratory viruses. By examining the structural mimicry of host cell receptors and their known biological functions, including antiviral activities, we assessed the ability of HMOs to bind and potentially inhibit viral proteins crucial for host cell entry. Our in silico analysis focused on viral proteins integral to host-virus interactions, namely the hemagglutinin protein of influenza, fusion proteins of respiratory syncytial and human metapneumovirus, and the spike protein of SARS-CoV-2. Using molecular docking and simulation studies, we demonstrated that HMOs exhibit varying binding affinities to these viral proteins, suggesting their potential as viral entry inhibitors. This study identified several HMOs with promising binding profiles, highlighting their potential in antiviral drug development. This research provides a foundation for utilizing HMOs as a natural source for designing new therapeutics, offering a novel approach in the fight against respiratory viral infections.
- Published
- 2024
- Full Text
- View/download PDF
5. Clinical trials for treatment of respiratory viral infections in recipients of haematopoietic cell transplantation and cellular therapies: are we on the right path to the finish line?
- Author
-
Sassine, Joseph, Hirsch, Hans H., and Chemaly, Roy F.
- Subjects
- *
CELL transplantation , *CELLULAR therapy , *VIRUS diseases , *RESPIRATORY infections , *CLINICAL trials - Published
- 2024
- Full Text
- View/download PDF
6. Targeting host-virus interactions: in silico analysis of the binding of human milk oligosaccharides to viral proteins involved in respiratory infections.
- Author
-
Mahaboob Ali, Anees Ahmed, Vishal, Adarsh, and Nelson, Everette Jacob Remington
- Abstract
Respiratory viral infections, a major public health concern, necessitate continuous development of novel antiviral strategies, particularly in the face of emerging and re-emerging pathogens. In this study, we explored the potential of human milk oligosaccharides (HMOs) as broad-spectrum antiviral agents against key respiratory viruses. By examining the structural mimicry of host cell receptors and their known biological functions, including antiviral activities, we assessed the ability of HMOs to bind and potentially inhibit viral proteins crucial for host cell entry. Our in silico analysis focused on viral proteins integral to host-virus interactions, namely the hemagglutinin protein of influenza, fusion proteins of respiratory syncytial and human metapneumovirus, and the spike protein of SARS-CoV-2. Using molecular docking and simulation studies, we demonstrated that HMOs exhibit varying binding affinities to these viral proteins, suggesting their potential as viral entry inhibitors. This study identified several HMOs with promising binding profiles, highlighting their potential in antiviral drug development. This research provides a foundation for utilizing HMOs as a natural source for designing new therapeutics, offering a novel approach in the fight against respiratory viral infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Respiratory viral detection in the plasma and cerebrospinal fluid (CSF) of young febrile infants.
- Author
-
Nicholson, Erin G., Avadhanula, Vasanthi, Sahni, Leila C., Ferlic‐Stark, Laura, Maurer, Lauren, Boom, Julie A., and Piedra, Pedro A.
- Subjects
- *
CEREBROSPINAL fluid , *INFANTS , *URINARY tract infections , *ENTEROVIRUS diseases , *RESPIRATORY syncytial virus , *VIRUS diseases - Abstract
Background: Respiratory viral infections are common in febrile infants ≤90 days. However, the detection of viruses other than enterovirus in the blood and cerebrospinal fluid (CSF) of young infants is not well defined. We sought to quantify the occurrence of respiratory viruses in the blood and CSF of febrile infants ≤90 days. Methods: We conducted a nested cohort study examining plasma and CSF samples from febrile infants 15–90 days via rtPCR. The samples were tested for respiratory viruses (respiratory syncytial virus, influenza, enterovirus, parechovirus, adenovirus, bocavirus). Clinical and laboratory data were also collected to determine the presence of serious bacterial infections (SBI). Results: Twenty‐four percent (30 of 126) of infants had plasma/CSF specimens positive for a respiratory virus. Enterovirus and parechovirus were the most commonly detected respiratory viruses. Viral positivity was highest in plasma samples at 25% (27 of 107) compared with CSF samples at 15% (nine of 62). SBIs (specifically urinary tract infections) were less common in infants with a sample positive for a respiratory virus compared to those without a virus detected (3% vs. 26%, p = 0.008). Conclusions: Our findings support the use of molecular diagnostics to include the identification of parechovirus in addition to enterovirus in febrile infants ≤90 days. Additionally, these data support the utilization of blood specimens to diagnose enterovirus and parechovirus infections in febrile infants ≤90 days. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Epidemiological surveillance of respiratory viral infections in SARS-CoV-2-negative samples during COVID-19 pandemic in Iran
- Author
-
Ali Maleki, Parvaneh Mehrbod, Farah Bokharaei-Salim, Sana Eybpoosh, Mahsa Tavakoli, Azita Eshratkhah Mohammadnejad, Zahra Hosseini, Setareh Kashanian, Laya Farhan Asadi, Mostafa Salehi-Vaziri, and Fatemeh Fotouhi
- Subjects
COVID-19 ,SARS-CoV-2 ,Respiratory viral Infections ,Epidemiological surveillance ,Syndromic surveillance ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background To improve the patient care, public health surveillance, and infection control, it is crucial to identify the presence and frequency of the common respiratory infections in individuals with COVID-19 symptoms but tested negative for SARS-CoV-2. This study aimed to shed light on this during the COVID-19 pandemic in Iran. Methods In this cross-sectional study, a total of 1,002 patients with acute respiratory infection who had negative SARS-CoV-2 test results and referred to Valfajr Health Center, the National Collaborating Laboratory of Influenza and COVID-19 National Reference Laboratory at Pasteur Institute of Iran were recruited between January 2020 and January 2022. Nasopharyngeal and oropharyngeal swab samples were collected to detect 17 common respiratory viruses via TaqMan one-step real-time multiplex PCR. Demographic and clinical data of the participants were obtained from their electronic medical records. Results In total, 218 samples (21.8%) were tested positive for at least one respiratory virus infection. Most of the common investigated respiratory viruses belonged to the years 2020 and 2022. The number of investigated patients in 2021 was few, which highlights the impact of health measures following the COVID-19 pandemic in Iran. Influenza A was the most common virus (5.8%), while adenovirus had the lowest prevalence (0.1%). Although the rate of respiratory virus infection was higher in men (24%) compared to women (19.3%), this difference was not statistically significant (P = 0.069). The prevalence of respiratory viruses had an inverse association with increasing age, with the highest rate (55.6%) observed in the age group below 2 years and the lowest rate (12.7%) in those above 65 years. Conclusion Our findings underscore the significance of adopting a comprehensive approach to respiratory infections detection and management. These results can be employed for the development of syndromic surveillance systems and implementation of the effective infection control measures. Furthermore, the results contribute to better understanding of the dynamics of respiratory viruses, both during pandemic periods and in non-pandemic contexts.
- Published
- 2023
- Full Text
- View/download PDF
9. Markers of antroponotic viral infections in vervet monkeys arrived from their natural habitat (Tanzania)
- Author
-
Dogadov I. Dmitriy, Karen K. Kyuregyan, Goncharenko M. Alexandra, Albert A. Minosyan, Armen A. Kochkonyan, Anastasia A. Karlsen, Oleg I. Vyshemirsky, Dzhina D. Karal-ogly, and Mikhail I. Mikhailov
- Subjects
vervet monkeys ,hemorrhagic fevers ,viral hepatitis ,herpesvirus infections ,respiratory viral infections ,intestinal viral infections ,elisa ,pcr ,Microbiology ,QR1-502 - Abstract
Introduction. Various human viruses have been identified in wild monkeys and in captive primates. Cases of transmission of viruses from wild monkeys to humans and vice versa are known. The aim of this study was to identify markers of anthroponotic viral infections in vervet monkeys (Chlorocebus pygerythrus) arrived from their natural habitat (Tanzania). Materials and methods. Fecal samples (n = 56) and blood serum samples (n = 75) obtained from 75 animals, respectively, on days 10 and 23 after admission to the primate center, were tested for the markers of anthroponotic viral infections (Ebola virus, Marburg virus, lymphocytic choriomeningitis, hepatitis C virus, herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein–Barr virus (EBV), parainfluenza types 1 and 3, intestinal adenoviruses, rotaviruses) by enzyme immunoassay (ELISA) and polymerase chain reaction (PCR). Results and discussion. Among the examined animals, markers of 6 out of 11 tested viral infections were identified. Detection rates of IgG antibodies to HSV-1,2 (15.9%) and CMV (15.9%) were two times as low as IgG antibodies to EBV (31.8%). Among the markers of respiratory viral infections, IgG antibodies to parainfluenza virus type 1 were found (6.8%). 14.3% of the animals had rotavirus antigen, and 94% had simian adenovirus DNA. Markers of hemorrhagic fevers Ebola, Marburg, LCM, hepatitis C, and type 3 parainfluenza were not detected. Conclusion. When importing monkeys from different regions of the world, an expanded screening for viral infections is needed considering the epidemiological situation both in the country of importation and in the country of destination.
- Published
- 2023
- Full Text
- View/download PDF
10. Neurological Impact of Respiratory Viruses: Insights into Glial Cell Responses in the Central Nervous System
- Author
-
Valentina P. Mora, Alexis M. Kalergis, and Karen Bohmwald
- Subjects
central nervous system ,respiratory viral infections ,glial cells ,microglia ,astrocytes ,Biology (General) ,QH301-705.5 - Abstract
Respiratory viral infections pose a significant public health threat, particularly in children and older adults, with high mortality rates. Some of these pathogens are the human respiratory syncytial virus (hRSV), severe acute respiratory coronavirus-2 (SARS-CoV-2), influenza viruses (IV), human parvovirus B19 (B19V), and human bocavirus 1 (HBoV1). These viruses cause various respiratory symptoms, including cough, fever, bronchiolitis, and pneumonia. Notably, these viruses can also impact the central nervous system (CNS), leading to acute manifestations such as seizures, encephalopathies, encephalitis, neurological sequelae, and long-term complications. The precise mechanisms by which these viruses affect the CNS are not fully understood. Glial cells, specifically microglia and astrocytes within the CNS, play pivotal roles in maintaining brain homeostasis and regulating immune responses. Exploring how these cells interact with viral pathogens, such as hRSV, SARS-CoV-2, IVs, B19V, and HBoV1, offers crucial insights into the significant impact of respiratory viruses on the CNS. This review article examines hRSV, SARS-CoV-2, IV, B19V, and HBoV1 interactions with microglia and astrocytes, shedding light on potential neurological consequences.
- Published
- 2024
- Full Text
- View/download PDF
11. Impact of respiratory viral infections during pregnancy on the neurological outcomes of the newborn: current knowledge.
- Author
-
Manti, Sara, Spoto, Giulia, Nicotera, Antonio Gennaro, Di Rosa, Gabriella, and Piedimonte, Giovanni
- Subjects
SARS-CoV-2 ,CORONAVIRUS diseases ,VIRUS diseases ,RESPIRATORY syncytial virus infections ,RESPIRATORY infections ,PREGNANCY outcomes - Abstract
Brain development is a complex process that begins during pregnancy, and the events occurring during this sensitive period can affect the offspring's neurodevelopmental outcomes. Respiratory viral infections are frequently reported in pregnant women, and, in the last few decades, they have been related to numerous neuropsychiatric sequelae. Respiratory viruses can disrupt brain development by directly invading the fetal circulation through vertical transmission or inducing neuroinflammation through the maternal immune activation and production of inflammatory cytokines. Influenza virus gestational infection has been consistently associated with psychotic disorders, such as schizophrenia and autism spectrum disorder, while the recent pandemic raised some concerns regarding the effects of severe acute respiratory syndrome coronavirus 2 on neurodevelopmental outcomes of children born to affected mothers. In addition, emerging evidence supports the possible role of respiratory syncytial virus infection as a risk factor for adverse neuropsychiatric consequences. Understanding the mechanisms underlying developmental dysfunction allows for improving preventive strategies, early diagnosis, and prompt interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
12. Prevention of respiratory viral infections in patients with chronic diseases.
- Author
-
Kritsyna, Anastasiia Borisovna, Vagabova, Khadizhat Shamilovna, Abasova, Aida Serazhudinovna, Deryabina, Ekaterina Alexandrovna, Musaev, Rasul Rasulovich, Biymurzaeva, Amina Tahirovna, and Markov, Alexander
- Abstract
Copyright of Revista Latinoamericana de Hipertension is the property of Revista Latinoamericana de Hipertension and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
13. Epidemiological surveillance of respiratory viral infections in SARS-CoV-2-negative samples during COVID-19 pandemic in Iran.
- Author
-
Maleki, Ali, Mehrbod, Parvaneh, Bokharaei-Salim, Farah, Eybpoosh, Sana, Tavakoli, Mahsa, Mohammadnejad, Azita Eshratkhah, Hosseini, Zahra, Kashanian, Setareh, Asadi, Laya Farhan, Salehi-Vaziri, Mostafa, and Fotouhi, Fatemeh
- Subjects
- *
COVID-19 pandemic , *RESPIRATORY infections , *VIRUS diseases , *PUBLIC health surveillance , *ELECTRONIC health records - Abstract
Background: To improve the patient care, public health surveillance, and infection control, it is crucial to identify the presence and frequency of the common respiratory infections in individuals with COVID-19 symptoms but tested negative for SARS-CoV-2. This study aimed to shed light on this during the COVID-19 pandemic in Iran. Methods: In this cross-sectional study, a total of 1,002 patients with acute respiratory infection who had negative SARS-CoV-2 test results and referred to Valfajr Health Center, the National Collaborating Laboratory of Influenza and COVID-19 National Reference Laboratory at Pasteur Institute of Iran were recruited between January 2020 and January 2022. Nasopharyngeal and oropharyngeal swab samples were collected to detect 17 common respiratory viruses via TaqMan one-step real-time multiplex PCR. Demographic and clinical data of the participants were obtained from their electronic medical records. Results: In total, 218 samples (21.8%) were tested positive for at least one respiratory virus infection. Most of the common investigated respiratory viruses belonged to the years 2020 and 2022. The number of investigated patients in 2021 was few, which highlights the impact of health measures following the COVID-19 pandemic in Iran. Influenza A was the most common virus (5.8%), while adenovirus had the lowest prevalence (0.1%). Although the rate of respiratory virus infection was higher in men (24%) compared to women (19.3%), this difference was not statistically significant (P = 0.069). The prevalence of respiratory viruses had an inverse association with increasing age, with the highest rate (55.6%) observed in the age group below 2 years and the lowest rate (12.7%) in those above 65 years. Conclusion: Our findings underscore the significance of adopting a comprehensive approach to respiratory infections detection and management. These results can be employed for the development of syndromic surveillance systems and implementation of the effective infection control measures. Furthermore, the results contribute to better understanding of the dynamics of respiratory viruses, both during pandemic periods and in non-pandemic contexts. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Impact of SARS-CoV-2 Prevention Measures on Non-SARS-CoV-2 Hospital-Onset Respiratory Viral Infections: An Incidence Trend Analysis From 2015–2023.
- Author
-
Ehrenzeller, Selina, Chen, Tom, Vaidya, Vineeta, Rhee, Chanu, Baker, Meghan A, and Klompas, Michael
- Subjects
- *
PREVENTION of infectious disease transmission , *MEDICAL masks , *RESPIRATORY syncytial virus , *COVID-19 , *CROSS infection , *RESPIRATORY infections , *MEDICAL screening , *SEASONAL influenza - Abstract
We reviewed hospital-onset respiratory viral infections, 2015–2023, in one hospital to determine whether Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission prevention measures prevented non-SARS-CoV-2 respiratory viral infections. Masking, employee symptom attestations, and screening patients and visitors for symptoms were associated with a 44%–53% reduction in hospital-onset influenza and respiratory syncytial virus (RSV), accounting for changes in community incidence. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Impact of respiratory viral infections during pregnancy on the neurological outcomes of the newborn: current knowledge
- Author
-
Sara Manti, Giulia Spoto, Antonio Gennaro Nicotera, Gabriella Di Rosa, and Giovanni Piedimonte
- Subjects
influenza virus ,maternal infection ,neurodevelopmental outcome ,respiratory syncytial virus ,respiratory viral infections ,severe acute respiratory syndrome coronavirus 2 ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Brain development is a complex process that begins during pregnancy, and the events occurring during this sensitive period can affect the offspring’s neurodevelopmental outcomes. Respiratory viral infections are frequently reported in pregnant women, and, in the last few decades, they have been related to numerous neuropsychiatric sequelae. Respiratory viruses can disrupt brain development by directly invading the fetal circulation through vertical transmission or inducing neuroinflammation through the maternal immune activation and production of inflammatory cytokines. Influenza virus gestational infection has been consistently associated with psychotic disorders, such as schizophrenia and autism spectrum disorder, while the recent pandemic raised some concerns regarding the effects of severe acute respiratory syndrome coronavirus 2 on neurodevelopmental outcomes of children born to affected mothers. In addition, emerging evidence supports the possible role of respiratory syncytial virus infection as a risk factor for adverse neuropsychiatric consequences. Understanding the mechanisms underlying developmental dysfunction allows for improving preventive strategies, early diagnosis, and prompt interventions.
- Published
- 2024
- Full Text
- View/download PDF
16. Co‐infections and immune‐evading viral hybrids: A perspective
- Author
-
Ryan Varghese, Dileep Kumar, Rohit Sharma, and Shopnil Akash
- Subjects
co‐infection ,immune evasion ,influenza A virus ,respiratory syncytial virus ,respiratory viral infections ,viral hybrid ,Medicine - Abstract
Abstract Background and Aims Co‐infections occur when two or more different types of pathogens infect the same host at the same time. Initially, it may develop via a primary infection and then later segue into a superinfection. Although some research suggests that coinfections do not affect the effect of disease outcomes, alternate evidence says otherwise. While the disease outcomes are frequently influenced by the interactions between many viruses, how these viruses interact during coinfections is poorly understood. This article aims to shed light on the interaction between viruses at a cellular and subcellular level, and the clinical implications for the same. Methods The articles were sought by conducting a thorough literature search on Google Scholar, ScienceDirect, PubMed, PubMed Central, Dimensions, and EBSCO Host, using keywords such as coinfections, virus, viral hybrids, and superinfection. The articles pertinent to the concept were then included. Results There is a growing body of evidence that suggests the formation of hybrid viral particles (HVPs) which conjugate at the cellular and subcellular level. While the formation of HVPs is bizarre, it may potentially have a profound effect on the clinical manifestations. Conclusion While there has been evidence of the formation of HVPs between a couple of viruses, researchers fear the existence of several other combinations, including zoonotic viruses. While this could be detrimental to the human race both at an individual—as well as a community‐level, an in‐depth understanding of the same may help in better management of the clinical manifestations of the disease.
- Published
- 2024
- Full Text
- View/download PDF
17. Respiratory viral infections in pediatric hematology/oncology patients
- Author
-
María E. Santolaya, Matías Delgado-Araneda, and Juan P. Torres
- Subjects
Respiratory viral infections ,Febrile neutropenia in children ,Pediatric hematology/oncology patients ,Infection susceptibility ,Molecular testing ,Cost-effectiveness ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Respiratory viral infections (RVIs) are the most frequent type of infection in the pediatric population, and are identified in up to 57 % of episodes of febrile neutropenia (FN). Nevertheless, they are frequently overlooked and have been historically considered inconsequential in infection treatment strategies for FN patients. Over the past two decades, a rekindled interest has provided insights into the epidemiology and clinical impact of RVIs in FN settings. This, along with the SARS-CoV-2 pandemic and its impact on molecular testing, as well as breakthroughs in immunology host-pathogen interactions, has set up the stage for re-instating the debate on RVIs role in FN. Capitalizing on these milestones, we propose a path to optimize diagnosis and treatment in RVIs afflicted FN patients, which could minimize hospitalizations and antimicrobial use. We also delve into the innate immunity's distinguishing features in response to RVIs, highlighting the importance of grounding therapeutic strategies in this understanding, while exploring the most recent research breakthroughs proposing immune-guided approaches that examine the impact of RVIs on host outcomes and susceptibility to co-infections. In conclusion, we call for future research to be geared toward enhancing RVIs diagnosis, understanding host-microorganism interactions more deeply, incorporating RVIs considerations into antimicrobial stewardship, and evaluating the cost-effectiveness of routine RVIs testing. This multifaceted approach could reduce antimicrobial resistance, as well as direct and indirect mortality rates in pediatric oncology.
- Published
- 2023
- Full Text
- View/download PDF
18. Editorial: Immune response to respiratory viruses and respiratory viral infections in susceptible populations
- Author
-
Paraskevi C. Fragkou, Dimitra Dimopoulou, Giulia De Angelis, Giulia Menchinelli, Roy F. Chemaly, and Chrysanthi Skevaki
- Subjects
respiratory viral infections ,immunology ,critical illness ,immunodeficiency ,immunosuppression ,Medicine (General) ,R5-920 - Published
- 2023
- Full Text
- View/download PDF
19. Case Report: ASCENIV use in three young children with immune abnormalities and acute respiratory failure secondary to RSV infection.
- Author
-
Bindernagel, Constance, Sotoudeh, Shannon, Minh Nguyen, Wetzstein, Gene, Sriaroon, Panida, and Walter, Jolan
- Subjects
RESPIRATORY syncytial virus infections ,ADULT respiratory distress syndrome ,BRONCHIOLITIS ,CHILD patients ,SEROTHERAPY ,VIRUS diseases - Abstract
Respiratory syncytial virus (RSV) is the most common etiology of bronchiolitis in young children. While most children clinically improve with care at home, RSV is the leading cause of hospitalization among infants aged 12 months or less. Common modalities of treatment for children with immune dysregulation include respiratory support and best supportive care, which may include immunoglobulin therapy. All immunoglobulin therapies adhere to Food and Drug Administration (FDA) - established standards for antibodies against measles, polio, and diphtheria, but there are no required standards for problematic respiratory viral pathogens, including RSV and others. ASCENIV is an approved IVIG that is manufactured from blending normal source plasma with plasma from donors that possess high antibody titers against RSV and other respiratory pathogens of concern. ASCENIV was developed, in part, to the unmet need that exists in immunocompromised patients who lack sufficient antibodies against problematic viral pathogens. ASCENIV is not a currently approved treatment for severe RSV and other viral infections. There is a lack of research regarding its potential benefits in the acute treatment period for RSV and in the pediatric population. Therefore, this case series was developed to describe real-world experiences of ASCENIV use in this less well studied clinical scenario. This case series reviews three pediatric patients ≤ 5 years of age with immune dysregulation and who were severely ill with RSV. Despite receiving best supportive care, and standard immunoglobulin therapy for some, the patients' clinical status continued to decline. All patients received ASCENIV in an intensive care setting. Each patient had ultimately recovered due to the various medical interventions done. This case series demonstrated that ASCENIV (500mg/kg) administration may have contributed to the treatment outcomes of a less well studied age-cohort of patients. In addition, no adverse side effects were observed after ASCENIV administration. Further analysis of the benefits of ASCENIV for the acute and preventative treatment in patients younger than 12 years of age with immune dysregulation should continue to be explored. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Co‐infections and immune‐evading viral hybrids: A perspective.
- Author
-
Varghese, Ryan, Kumar, Dileep, Sharma, Rohit, and Akash, Shopnil
- Subjects
MIXED infections ,INFECTION ,SYMPTOMS ,HUMAN beings ,VIRUS diseases - Abstract
Background and Aims: Co‐infections occur when two or more different types of pathogens infect the same host at the same time. Initially, it may develop via a primary infection and then later segue into a superinfection. Although some research suggests that coinfections do not affect the effect of disease outcomes, alternate evidence says otherwise. While the disease outcomes are frequently influenced by the interactions between many viruses, how these viruses interact during coinfections is poorly understood. This article aims to shed light on the interaction between viruses at a cellular and subcellular level, and the clinical implications for the same. Methods: The articles were sought by conducting a thorough literature search on Google Scholar, ScienceDirect, PubMed, PubMed Central, Dimensions, and EBSCO Host, using keywords such as coinfections, virus, viral hybrids, and superinfection. The articles pertinent to the concept were then included. Results: There is a growing body of evidence that suggests the formation of hybrid viral particles (HVPs) which conjugate at the cellular and subcellular level. While the formation of HVPs is bizarre, it may potentially have a profound effect on the clinical manifestations. Conclusion: While there has been evidence of the formation of HVPs between a couple of viruses, researchers fear the existence of several other combinations, including zoonotic viruses. While this could be detrimental to the human race both at an individual—as well as a community‐level, an in‐depth understanding of the same may help in better management of the clinical manifestations of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Editorial: Omics in respiratory virus infectious diseases: integrating multi-omics to reveal data characteristics and mechanisms for the diagnosis and treatment of disease
- Author
-
Xuerui Wang and Luis Ulloa
- Subjects
multi-omics ,respiratory infection ,virus infection ,pneumonia - clinical features and management ,respiratory viral infections ,Medicine (General) ,R5-920 - Published
- 2023
- Full Text
- View/download PDF
22. Case Report: ASCENIV use in three young children with immune abnormalities and acute respiratory failure secondary to RSV infection
- Author
-
Constance Bindernagel, Shannon Sotoudeh, Minh Nguyen, Gene Wetzstein, Panida Sriaroon, and Jolan Walter
- Subjects
RSV ,ASCENIV ,pediatric ,immunodeficiency ,immune dysregulation ,respiratory viral infections ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Respiratory syncytial virus (RSV) is the most common etiology of bronchiolitis in young children. While most children clinically improve with care at home, RSV is the leading cause of hospitalization among infants aged 12 months or less. Common modalities of treatment for children with immune dysregulation include respiratory support and best supportive care, which may include immunoglobulin therapy. All immunoglobulin therapies adhere to Food and Drug Administration (FDA) - established standards for antibodies against measles, polio, and diphtheria, but there are no required standards for problematic respiratory viral pathogens, including RSV and others. ASCENIV is an approved IVIG that is manufactured from blending normal source plasma with plasma from donors that possess high antibody titers against RSV and other respiratory pathogens of concern. ASCENIV was developed, in part, to the unmet need that exists in immunocompromised patients who lack sufficient antibodies against problematic viral pathogens. ASCENIV is not a currently approved treatment for severe RSV and other viral infections. There is a lack of research regarding its potential benefits in the acute treatment period for RSV and in the pediatric population. Therefore, this case series was developed to describe real-world experiences of ASCENIV use in this less well studied clinical scenario. This case series reviews three pediatric patients ≤ 5 years of age with immune dysregulation and who were severely ill with RSV. Despite receiving best supportive care, and standard immunoglobulin therapy for some, the patients’ clinical status continued to decline. All patients received ASCENIV in an intensive care setting. Each patient had ultimately recovered due to the various medical interventions done. This case series demonstrated that ASCENIV (500mg/kg) administration may have contributed to the treatment outcomes of a less well studied age-cohort of patients. In addition, no adverse side effects were observed after ASCENIV administration. Further analysis of the benefits of ASCENIV for the acute and preventative treatment in patients younger than 12 years of age with immune dysregulation should continue to be explored.
- Published
- 2023
- Full Text
- View/download PDF
23. Cardiovascular Complications in Respiratory Viral Infections with a Focus on COVID-19.
- Author
-
Aleebrahim-Dehkordi, Elahe, Mohebalizadeh, Mehdi, Ganjirad, Zahra, Torabi, Sara, Hooshyar, Dariush, and Saghazadeh, Amene
- Subjects
- *
MIDDLE East respiratory syndrome , *SARS disease , *VIRUS diseases , *COVID-19 , *RESPIRATORY infections - Abstract
Patients with respiratory viral infections have altered immune responses, which may predispose them to cardiovascular complications. In the face of the pandemic of a new kind of severe acute respiratory syndrome (SARS), coronavirus disease 2019 (COVID-19), there is a resurgence of interest in the early diagnosis, prevention, and treatment of patients who are at risk. COVID-19 often manifests as viral pneumonia, although extrapulmonary manifestations are also common. Acute cardiac damage associated with elevated high-sensitivity troponin levels crucially contributes to mortality in severe COVID-19. The present review clinically compares cardiovascular complications between COVID-19 and other respiratory infections caused by single-stranded RNA viruses, namely influenza, SARS, and Middle East respiratory syndrome (MERS). Estimating the death rate from RVIs has been a subject of intense research, but the mortality from cardiovascular complications in these infections is less understood and calls for further research. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation.
- Author
-
Seow, Han Cong, Cai, Jian-Piao, Pan, Harry Weijie, Luo, Cuiting, Wen, Kun, Situ, Jianwen, Wang, Kun, Cao, Hehe, Leung, Susan W.S., Yuan, Shuofeng, and Lam, Jenny K.W.
- Subjects
- *
SARS-CoV-2 Delta variant , *MONOCLONAL antibodies , *LUNGS , *SPRAY drying , *GEL permeation chromatography , *VIRUS diseases , *SARS-CoV-2 , *POWDERS - Abstract
Neutralising monoclonal antibody (mAb) is an important weapon in our arsenal for combating respiratory viral infections. However, the effectiveness of neutralising mAb has been impeded by the rapid emergence of mutant variants. Early administration of broad-spectrum mAb with improved delivery efficiency can potentially enhance efficacy and patient outcomes. WKS13 is a humanised mAb which was previously demonstrated to exhibit broad-spectrum activity against SARS-CoV-2 variants. In this study, a dual targeting formulation strategy was designed to deliver WKS13 to both the nasal cavity and lower airways, the two critical sites of infection caused by SARS-CoV-2. Dry powders of WKS13 were first prepared by spray drying, with cyclodextrin used as stabiliser excipient. Two-fluid nozzle (TFN) was used to produce particles below 5 μm for lung deposition (C-TFN formulation) and ultrasonic nozzle (USN) was used to produce particles above 10 μm for nasal deposition (C-USN formulation). Gel electrophoresis and size exclusion chromatography studies showed that the structural integrity of mAb was successfully preserved with no sign of aggregation after spray drying. To achieve dual targeting property, C-TFN and C-USN were mixed at various ratios. The aerosolisation property of the mixed formulations dispersed from a nasal powder device was examined using a Next Generation Impactor (NGI) coupled with a glass expansion chamber. When the ratio of C-TFN in the mixed formulation increased, the fraction of particles deposited in the lung increased proportionally while the fraction of particles deposited in the nasal cavity decreased correspondingly. A customisable aerosol deposition profile could therefore be achieved by manipulating the mixing ratio between C-TFN and C-USN. Dual administration of C-TFN and C-USN powders to the lung and nasal cavity of hamsters, respectively, was effective in offering prophylactic protection against SARS-CoV-2 Delta variant. Viral loads in both the lung tissues and nasal wash were significantly reduced, and the efficacy was comparable to systemic administration of unformulated WKS13. Overall, dual targeting powder formulation of neutralising mAb is a promising approach for prophylaxis of respiratory viral infections. The ease and non-invasive administration of dual targeting nasal powder may facilitate the widespread distribution of neutralising mAb during the early stage of unpredictable outbreaks. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Vitamin D in respiratory viral infections: a key immune modulator?
- Author
-
Vaghari-Tabari, Mostafa, Mohammadzadeh, Iraj, Qujeq, Durdi, Majidinia, Maryam, Alemi, Forough, Younesi, Simin, Mahmoodpoor, Ata, Maleki, Masomeh, Yousefi, Bahman, and Asemi, Zatollah
- Subjects
- *
VITAMIN D , *RESPIRATORY infections , *IMMUNOMODULATORS , *VIRUS diseases , *COVID-19 pandemic , *VITAMIN D deficiency - Abstract
Respiratory viral infections are common respiratory diseases. Influenza viruses, RSV and SARS-COV2 have the potential to cause severe respiratory infections. Numerous studies have shown that unregulated immune response to these viruses can cause excessive inflammation and tissue damage. Therefore, regulating the antiviral immune response in the respiratory tract is of importance. In this regard, recent years studies have emphasized the importance of vitamin D in respiratory viral infections. Although, the most well-known role of vitamin D is to regulate the metabolism of phosphorus and calcium, it has been shown that this vitamin has other important functions. One of these functions is immune regulation. Vitamin D can regulate the antiviral immune response in the respiratory tract in order to provide an effective defense against respiratory viral infections and prevention from excessive inflammatory response and tissue damage. In addition, this vitamin has preventive effects against respiratory viral infections. Some studies during the COVID-19 pandemic have shown that vitamin D deficiency may be associated with a higher risk of mortality and sever disease in patients with COVID-19. Since, more attention has recently been focused on vitamin D. In this article, after a brief overview of the antiviral immune response in the respiratory system, we will review the role of vitamin D in regulating the antiviral immune response comprehensively. Then we will discuss the importance of this vitamin in influenza, RSV, and COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Repositioned Natural Compounds and Nanoformulations: A Promising Combination to Counteract Cell Damage and Inflammation in Respiratory Viral Infections.
- Author
-
Mariano, Alessia, Bigioni, Irene, Marchetti, Magda, Scotto d'Abusco, Anna, and Superti, Fabiana
- Subjects
- *
VIRUS diseases , *RESPIRATORY infections , *RESVERATROL , *DRUG discovery , *DRUG repositioning , *RESPIRATORY diseases - Abstract
Respiratory viral diseases are among the most important causes of disability, morbidity, and death worldwide. Due to the limited efficacy or side effects of many current therapies and the increase in antiviral-resistant viral strains, the need to find new compounds to counteract these infections is growing. Since the development of new drugs is a time-consuming and expensive process, numerous studies have focused on the reuse of commercially available compounds, such as natural molecules with therapeutic properties. This phenomenon is generally called drug repurposing or repositioning and represents a valid emerging strategy in the drug discovery field. Unfortunately, the use of natural compounds in therapy has some limitations, due to their poor kinetic performance and consequently reduced therapeutic effect. The advent of nanotechnology in biomedicine has allowed this limitation to be overcome, showing that natural compounds in nanoform may represent a promising strategy against respiratory viral infections. In this narrative review, the beneficial effects of some promising natural molecules, curcumin, resveratrol, quercetin, and vitamin C, which have been already studied both in native form and in nanoform, against respiratory viral infections are presented and discussed. The review focuses on the ability of these natural compounds, analyzed in in vitro and in vivo studies, to counteract inflammation and cellular damage induced by viral infection and provide scientific evidence of the benefits of nanoformulations in increasing the therapeutic potential of these molecules. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections.
- Author
-
Loo, Ching-Yee, Lee, Wing-Hin, and Zhou, Qi Tony
- Subjects
- *
RESPIRATORY syncytial virus infections , *RESPIRATORY infections , *VIRUS diseases , *INHALATION administration , *RECOMBINANT proteins , *PLANT viruses - Abstract
With the rapid outbreak of respiratory viral infections, various biological (e.g. vaccines, peptides, recombinant proteins, antibodies and genes) and antiviral agents (e.g. ribavirin, palivizumab and valaciclovir) have been successfully developed for the treatment of respiratory virus infections such as influenza, respiratory syncytial virus and SARS-CoV-2 infections. These therapeutics are conventionally delivered via oral, intramuscular or injection route and are associated with several adverse events due to systemic toxicity. The inherent in vivo instability of biological therapeutics may hinder them from being administered without proper formulations. Therefore, we have witnessed a boom in nanotechnology coupled with a needle-free administration approach such as the inhalation route for the delivery of complex therapeutics to treat respiratory infections. This review discussed the recent advances in the inhalation strategies of nanoformulations that target virus respiratory infections. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Brain Lesions in Perinatal Infections
- Author
-
Zinserling, Vsevolod and Zinserling, Vsevolod
- Published
- 2022
- Full Text
- View/download PDF
29. Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections.
- Author
-
Needham, David
- Subjects
- *
INTRANASAL medication , *RESPIRATORY infections , *AQUEOUS solutions , *SALINE solutions , *SARS-CoV-2 , *SOLVENT extraction - Abstract
Motivation: The low solubility, weak acid drug, niclosamide is a host cell modulator with broad-spectrum anti-viral cell-activity against many viruses, including stopping the SARS-CoV-2 virus from infecting cells in cell culture. As a result, a simple universal nasal spray preventative was proposed and investigated in earlier work regarding the dissolution of niclosamide into simple buffers. However, starting with pharmaceutical grade, niclosamide represents a new 505(b)(2) application. The motivation for this second paper in the series was therefore to explore if and to what extent niclosamide could be extracted from commercially available and regulatory-approved niclosamide oral tablets that could serve as a preventative nasal spray and an early treatment oral/throat spray, with possibly more expeditious testing and regulatory approval. Experimental: Measurements of supernatant niclosamide concentrations were made by calibrated UV-Vis for the dissolution of niclosamide from commercially available Yomesan crushed into a powder for dissolution into Tris Buffer (TB) solutions. Parameters tested were as follows: time (0–2 days), concentration (300 µM to -1 mM), pH (7.41 to 9.35), and anhydrous/hydrated state. Optical microscopy was used to view the morphologies of the initial crushed powder, and the dissolving and equilibrating undissolved excess particles to detect morphologic changes that might occur. Results: Concentration dependence: Niclosamide was readily extracted from powdered Yomesan at pH 9.34 TB at starting Yomesan niclosamide equivalents concentrations of 300 µM, 600 µM, and 1 mM. Peak dissolved niclosamide supernatant concentrations of 264 µM, 216 µM, and 172 µM were achieved in 1 h, 1 h, and 3 h respectively. These peaks though were followed by a reduction in supernatant concentration to an average of 112.3 µM ± 28.4 µM after overnight stir on day 2. pH dependence: For nominal pHs of 7.41, 8.35, 8.85, and 9.35, peak niclosamide concentrations were 4 µM, 22.4 µM, 96.2 µM, and 215.8 µM, respectively. Similarly, the day 2 values all reduced to 3 µM, 12.9 µM, 35.1 µM, and 112.3 µM. A heat-treatment to 200 °C dehydrated the niclosamide and showed a high 3 h concentration (262 µM) and the least day-2 reduction (to 229 µM). This indicated that the presence, or formation during exposure to buffer, of lower solubility polymorphs was responsible for the reductions in total solubilities. These morphologic changes were confirmed by optical microscopy that showed initially featureless particulate-aggregates of niclosamide could grow multiple needle-shaped crystals and form needle masses, especially in the presence of Tris-buffered sodium chloride, where new red needles were rapidly made. Scale up: A scaled-up 1 L solution of niclosamide was made achieving 165 µM supernatant niclosamide in 3 h by dissolution of just one fifth (100 mg niclosamide) of a Yomesan tablet. Conclusion: These comprehensive results provide a guide as to how to utilize commercially available and approved tablets of niclosamide to generate aqueous niclosamide solutions from a simple dissolution protocol. As shown here, just one 4-tablet pack of Yomesan could readily make 165 L of a 20 µM niclosamide solution giving 16,500 10 mL bottles. One million bottles, from just 60 packs of Yomesan, would provide 100 million single spray doses for distribution to mitigate a host of respiratory infections as a universal preventative-nasal and early treatment oral/throat sprays throughout the world. pH dependence of niclosamide extraction from crushed Yomesan tablet material into Tris buffer (yellow-green in vial) and Tris-buffered saline solution (orange-red in vial). Initial anhydrous dissolution concentration is reduced by overnight stirring to likely monohydrate niclosamide; and is even lower if in TBSS forming new niclosamide sodium needle crystals grown from the original particles. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Impact of human coronavirus infections on paediatric patients at a tertiary paediatric hospital: a retrospective study of the prepandemic era.
- Author
-
Alsulami, A.O., Chahine, R., Kong, M., Kimberlin, D.W., Whitley, R.J., and James, S.H.
- Abstract
Human coronaviruses (HCoVs) are important respiratory pathogens in humans and animals. Most HCoVs are emerging pathogens, with five known human pathogens identified in the last two decades. To examine the clinical course of HCoV infection in children to improve understanding of severity and outcomes. A retrospective review was undertaken of all encounters of children with known HCoV infection at a tertiary paediatric hospital from January 2015 to January 2018. Electronic medical records were reviewed for demographic data, HCoV type, viral co-pathogens, time to testing, need for hospitalization, requirement for higher-level care (HLC) including intensive care unit management and requirement for oxygen support, radiographic findings suggestive of lower respiratory tract (LRT) disease, and length of stay (LOS). In total, 450 encounters for 430 different patients were identified, with the majority (85%) being inpatient. OC43 was the most common HCoV. Younger patients (age <5 years) had higher probability of hospitalization [adjusted odds ratio (aOR) 2.2, 95% confidence interval (CI) 1.2–4.1], requirement for HLC (aOR 1.8, 95% CI 1.0–3.1) and presence of LRT findings on chest radiographs (aOR 1.7, 95% CI 1.01–2.9). Clinical outcomes did not differ between HCoV types, except LOS which was longer for 229E. Fifty-two (11%) encounters were detected after 3 days of hospitalization (median 25.5 days), suggesting possible nosocomial infection. HCoVs are important respiratory pathogens in the paediatric population, especially among patients aged <5 years who are at increased risk for severe disease. The role of HCoVs as hospital-acquired pathogens may be underappreciated. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. The Landscape of Expressed Chimeric Transcripts in the Blood of Severe COVID-19 Infected Patients.
- Author
-
Mukherjee, Sunanda Biswas, Detroja, Rajesh, Mukherjee, Sumit, and Frenkel-Morgenstern, Milana
- Subjects
- *
COVID-19 , *VIRUS diseases , *COVID-19 pandemic , *RESPIRATORY infections , *SARS-CoV-2 - Abstract
The ongoing COVID-19 pandemic caused by SARS-CoV-2 infections has quickly developed into a global public health threat. COVID-19 patients show distinct clinical features, and in some cases, during the severe stage of the condition, the disease severity leads to an acute respiratory disorder. In spite of several pieces of research in this area, the molecular mechanisms behind the development of disease severity are still not clearly understood. Recent studies demonstrated that SARS-CoV-2 alters the host cell splicing and transcriptional response to overcome the host immune response that provides the virus with favorable conditions to replicate efficiently within the host cells. In several disease conditions, aberrant splicing could lead to the development of novel chimeric transcripts that could promote the functional alternations of the cell. As severe SARS-CoV-2 infection was reported to cause abnormal splicing in the infected cells, we could expect the generation and expression of novel chimeric transcripts. However, no study so far has attempted to check whether novel chimeric transcripts are expressed in severe SARS-CoV-2 infections. In this study, we analyzed several publicly available blood transcriptome datasets of severe COVID-19, mild COVID-19, other severe respiratory viral infected patients, and healthy individuals. We identified 424 severe COVID-19 -specific chimeric transcripts, 42 of which were recurrent. Further, we detected 189 chimeric transcripts common to severe COVID-19 and multiple severe respiratory viral infections. Pathway and gene enrichment analysis of the parental genes of these two subsets of chimeric transcripts reveals that these are potentially involved in immune-related processes, interferon signaling, and inflammatory responses, which signify their potential association with immune dysfunction leading to the development of disease severity. Our study provides the first detailed expression landscape of chimeric transcripts in severe COVID-19 and other severe respiratory viral infections. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Safety in Rats of a Novel Nasal Spray Formulation for the Prevention of Airborne Viral Infections.
- Author
-
Tanori, Mirella, Pitaro, Michele, Fratini, Emiliano, Colantoni, Eleonora, Amoresano, Angela, Celentano, Simona, Chiaramonte, Barbara, and Mancuso, Mariateresa
- Subjects
- *
AIRBORNE infection , *VIRUS diseases , *INTRANASAL medication , *NASAL mucosa , *VIRAL transmission , *RATS , *SALINE solutions - Abstract
Hexedra+® is a nasal spray containing hydroxypropyl methylcellulose, beta-cyclodextrin, and usnic acid. It has been developed with the aim of reducing the risk of transmission of airborne viral infections, with particular reference to influenza and COVID-19. As part of the preclinical development of the product, we carried out a study on thirty male Wistar rats divided into three study groups and treated with Hexedra+, an alternative formulation containing a double concentration of usnic acid (0.015% instead of 0.0075%) or saline solution. Products were administered at the dose of 30 μL into each nostril, three times a day for seven consecutive days by means of a micropipette. By the end of the treatment period, no significant changes were observed in body weight. Histological examination of nasal mucosa and soft organs did not show any significant difference in the three study groups. Serum transaminase level remained in the normal limit in all the animals treated. The serum level of usnic acid was measured in order to assess the absorption of the molecule through the nasal mucosa. By the end of the study period, the usnic acid serum level was negligible in all the animals treated. In conclusion, the safety profile of Hexedra+ appears favorable in the animal model studied. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Population‐based hospitalization burden estimates for respiratory viruses, 2015–2019.
- Author
-
Zimmerman, Richard K., Balasubramani, G. K., D'Agostino, Helen E. A., Clarke, Lloyd, Yassin, Mohamed, Middleton, Donald B., Silveira, Fernanda P., Wheeler, Nicole D., Landis, Jonathan, Peterson, Alanna, Suyama, Joe, Weissman, Alexandra, and Nowalk, Mary Patricia
- Subjects
- *
RESPIRATORY syncytial virus , *RHINOVIRUSES , *HOSPITAL care , *ELECTRONIC health records , *RESPIRATORY infections , *HEALTH policy , *ELECTRONIC systems - Abstract
Background: Acute respiratory infections (ARIs) result in millions of illnesses and hundreds of thousands of hospitalizations annually in the United States. The responsible viruses include influenza, parainfluenza, human metapneumovirus, coronaviruses, respiratory syncytial virus (RSV), and human rhinoviruses. This study estimated the population‐based hospitalization burden of those respiratory viruses (RVs) over 4 years, from July 1, 2015 to June 30, 2019, among adults ≥18 years of age for Allegheny County (Pittsburgh), Pennsylvania. Methods: We used population‐based statewide hospital discharge data, health system electronic medical record (EMR) data for RV tests, census data, and a published method to calculate burden. Results: Among 26,211 eligible RV tests, 67.6% were negative for any virus. The viruses detected were rhinovirus/enterovirus (2552; 30.1%), influenza A (2,299; 27.1%), RSV (1082; 12.7%), human metapneumovirus (832; 9.8%), parainfluenza (601; 7.1%), influenza B (565; 6.7%), non‐SARS‐CoV‐2 coronavirus (420; 4.9% 1.5 years of data available), and adenovirus (136; 1.6%). Most tests were among female (58%) and White (71%) patients with 60% of patients ≥65 years, 24% 50–64 years, and 16% 18–49 years. The annual burden ranged from 137–174/100,000 population for rhinovirus/enterovirus; 99–182/100,000 for influenza A; and 56–81/100,000 for RSV. Among adults <65 years, rhinovirus/enterovirus hospitalization burden was higher than influenza A; whereas the reverse was true for adults ≥65 years. RV hospitalization burden increased with increasing age. Conclusions: These virus‐specific ARI population‐based hospital burden estimates showed significant non‐influenza burden. These estimates can serve as the basis for several areas of research that are essential for setting funding priorities and guiding public health policy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. The Use of PCR for Respiratory Virus Detection on the Diagnosis and Treatment Decision of Respiratory Tract Infections in Iraq
- Author
-
Hany Akeel Al-hussaniy, Raghid R. Altalebi, Ali H. Albu-Rghaif, and Abdul-Ghaffar A. Abdul-Amir
- Subjects
respiratory viral infections ,pr filmarray ,antibiotics ,antimicrobial resistance ,Microbiology ,QR1-502 - Abstract
Diseases of the respiratory system are a common cause of antibiotic prescription in Iraq and worldwide. Technology has been recently used for its diagnosis, such as the Film Array Respiratory Panel. This study aims to identify the correlation between the diagnosis and treatment of respiratory tract infections with the result of polymerase chain reaction (PCR) for respiratory viruses. A descriptive, cross-sectional, retrospective study included 134 patients treated at Alkharama Hospital and the Private Hospital in Baghdad, Iraq, in the period from January 2020 to March 2020 For all cases, the results of the panel and the treatment received by the patients were analysed. 58% received antibiotic treatment upon admission, 13% combined treatment (antibiotic + antiviral), 27% received symptomatic treatment, and 2% were treated with the first-instance antiviral. After the result, 38% continued with antibiotics, 30% with antibiotics and antivirals, 13.8% with antivirals and 18.2% with symptomatic treatment. Despite the worldwide alarm over antimicrobial resistance, patients continue to be treated with antibiotics due to a situation that is influenced by several factors.
- Published
- 2022
- Full Text
- View/download PDF
35. Mucosal immunity and vaccines against viral infections
- Author
-
S. S. Zainutdinov, G. F. Sivolobova, V. B. Loktev, and G. V. Kochneva
- Subjects
review ,mucous membranes ,mucosal vaccines ,class a immunoglobulins (iga) ,respiratory viral infections ,Microbiology ,QR1-502 - Abstract
Mucosal immunity is realized through a structural and functional system called mucose-associated lymphoid tissue (MALT). MALT is subdivided into parts (clusters) depending on their anatomical location, but they all have a similar structure: mucus layer, epithelial tissue, lamina propria and lymphoid follicles. Plasma cells of MALT produce a unique type of immunoglobulins, IgA, which have the ability to polymerize. In mucosal immunization, the predominant form of IgA is a secretory dimer, sIgA, which is concentrated in large quantities in the mucosa. Mucosal IgA acts as a first line of defense and neutralizes viruses efficiently at the portal of entry, preventing infection of epithelial cells and generalization of infection. To date, several mucosal antiviral vaccines have been licensed, which include attenuated strains of the corresponding viruses: poliomyelitis, influenza, and rotavirus. Despite the tremendous success of these vaccines, in particular, in the eradication of poliomyelitis, significant disadvantages of using attenuated viral strains in their composition are the risk of reactogenicity and the possibility of reversion to a virulent strain during vaccination. Nevertheless, it is mucosal vaccination, which mimics a natural infection, is able to induce a fast and effective immune response and thus help prevent and possibly stop outbreaks of many viral infections. Currently, a number of intranasal vaccines based on a new vector approach are successfully undergoing clinical trials. In these vaccines, the safe viral vectors are used to deliver protectively significant immunogens of pathogenic viruses. The most tested vector for intranasal vaccines is adenovirus, and the most significant immunogen is SARSCoV-2 S protein. Mucosal vector vaccines against human respiratory syncytial virus and human immunodeficiency virus type 1 based on Sendai virus, which is able to replicate asymptomatically in cells of bronchial epithelium, are also being investigated.
- Published
- 2022
- Full Text
- View/download PDF
36. Considerations for de-escalating universal masking in healthcare centers
- Author
-
Caroline Landelle, Gabriel Birgand, James R. Price, Nico T. Mutters, Daniel J. Morgan, Jean-Christophe Lucet, Solen Kerneis, and Walter Zingg
- Subjects
COVID-19 ,healthcare setting ,infection control ,universal masking ,medical face mask ,respiratory viral infections ,Infectious and parasitic diseases ,RC109-216 ,Public aspects of medicine ,RA1-1270 - Abstract
Three years after the beginning of the COVID-19 pandemic, better knowledge on the transmission of respiratory viral infections (RVI) including the contribution of asymptomatic infections encouraged most healthcare centers to implement universal masking. The evolution of the SARS-CoV-2 epidemiology and improved immunization of the population call for the infection and prevention control community to revisit the masking strategy in healthcare. In this narrative review, we consider factors for de-escalating universal masking in healthcare centers, addressing compliance with the mask policy, local epidemiology, the level of protection provided by medical face masks, the consequences of absenteeism and presenteeism, as well as logistics, costs, and ecological impact. Most current national and international guidelines for mask use are based on the level of community transmission of SARS-CoV-2. Actions are now required to refine future recommendations, such as establishing a list of the most relevant RVI to consider, implement reliable local RVI surveillance, and define thresholds for activating masking strategies. Considering the epidemiological context (measured via sentinel networks or wastewater analysis), and, if not available, considering a time period (winter season) may guide to three gradual levels of masking: (i) standard and transmission-based precautions and respiratory etiquette, (ii) systematic face mask wearing when in direct contact with patients, and (iii) universal masking. Cost-effectiveness analysis of the different strategies is warranted in the coming years. Masking is just one element to be considered along with other preventive measures such as staff and patient immunization, and efficient ventilation.
- Published
- 2023
- Full Text
- View/download PDF
37. The clinical and genomic epidemiology of seasonal human coronaviruses in congregate homeless shelter settings: A repeated cross-sectional study
- Author
-
Eric J. Chow, Amanda M. Casto, Julia H. Rogers, Pavitra Roychoudhury, Peter D. Han, Hong Xie, Margaret G. Mills, Tien V. Nguyen, Brian Pfau, Sarah N. Cox, Caitlin R. Wolf, James P. Hughes, Timothy M. Uyeki, Melissa A. Rolfes, Emily Mosites, M. Mia Shim, Jeffrey S. Duchin, Nancy Sugg, Lea A. Starita, Janet A. Englund, and Helen Y. Chu
- Subjects
Human coronavirus ,Homeless shelters ,Respiratory viral infections ,Homelessness ,Public aspects of medicine ,RA1-1270 - Abstract
Summary: Background: The circulation of respiratory viruses poses a significant health risk among those residing in congregate settings. Data are limited on seasonal human coronavirus (HCoV) infections in homeless shelter settings. Methods: We analysed data from a clinical trial and SARS-CoV-2 surveillance study at 23 homeless shelter sites in King County, Washington between October 2019-May 2021. Eligible participants were shelter residents aged ≥3 months with acute respiratory illness. We collected enrolment data and nasal samples for respiratory virus testing using multiplex RT-PCR platform including HCoV. Beginning April 1, 2020, eligibility expanded to shelter residents and staff regardless of symptoms. HCoV species was determined by RT-PCR with species-specific primers, OpenArray assay or genomic sequencing for samples with an OpenArray relative cycle threshold
- Published
- 2022
- Full Text
- View/download PDF
38. پيش بينى كنند ه هاى رفتارهاى پيشگيرانه از عفونت هاى ويروسى حاد تنفسى شايع د ر ميان آرايشگران زن شهر اروميه: كاربرد نظريه انگيزش محافظت توسعه يافته.
- Author
-
آزيتا خويش كار, عليرضا د يد ارلو, حميد رضا خلخالى, and مينا ماهرى
- Subjects
- *
PROTECTION motivation theory , *VIRUS diseases , *INFECTIOUS disease transmission , *RESPIRATORY infections , *HAIRDRESSERS , *CARRIER state (Communicable diseases) - Abstract
Background and Objective: In hairdressers, for various reasons, the potential for transmission and spread of infectious diseases is high. On the other hand, adopting preventive behaviors is one of the main ways to control and prevent these diseases. Therefore, the aim of this study was to determine the predictors of preventive behaviors against the common acute respiratory viral infections based on the constructs of Extended Protection Motivation Theory among the female hairdressers in Urmia. Materials and Methods: In the present cross-sectional study, 400 female hairdressers were entered by multi-stage sampling method. The data collection instrument was a researcher-made questionnaire containing of two sections. The first section was demographic information and the second section was questions related to the Extended Protection Motivation Theory constructs about the common acute respiratory viral infections. Data analysis was performed using SPSS 16 software. Results: Perceived self-efficacy (β=0.348, p<0.001), response costs (β=-0.169, p=0.002), perceived severity (β=0.168, p=0.002), protection motivation (β=0.140, p=0.041), and knowledge (β=0.124, p=0.005), respectively the most power, were predictors of preventive behaviors against the common acute respiratory viral infections. Extended Protection Motivation Theory constructs explained about 37% of the variance of preventive behaviors against the common acute respiratory viral infections among the female hairdressers in Urmia. Conclusion: Constructs of perceived self-efficacy, response costs, perceived severity, protection motivation, and knowledge can be used to develop and implement educational interventions related to the promotion of preventive behaviors against the common acute respiratory viral infections among the female hairdressers in Urmia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Antioxidant Effects of Dietary Supplements on Adult COVID-19 Patients: Why Do We Not Also Use Them in Children?
- Author
-
Notarbartolo, Veronica, Montante, Claudio, Ferrante, Giuliana, and Giuffrè, Mario
- Subjects
COVID-19 ,CORONAVIRUS diseases ,SARS-CoV-2 ,DIETARY supplements ,VIRUS diseases ,RESPIRATORY syncytial virus - Abstract
Respiratory tract infections (RTIs) are very common in children, especially in the first five years of life, and several viruses, such as the influenza virus, Respiratory Syncytial Virus, and Rhinovirus, are triggers for symptoms that usually affect the upper airways. It has been known that during respiratory viral infections, a condition of oxidative stress (OS) occurs, and many studies have suggested the potential use of antioxidants as complementary components in prophylaxis and/or therapy of respiratory viral infections. Preliminary data have demonstrated that antioxidants may also interfere with the new coronavirus 2's entry and replication in human cells, and that they have a role in the downregulation of several pathogenetic mechanisms involved in disease severity. Starting from preclinical data, the aim of this narrative review is to evaluate the current evidence about the main antioxidants that are potentially useful for preventing and treating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in adults and to speculate on their possible use in children by exploring the most relevant issues affecting their use in clinical practice, as well as the associated evidence gaps and research limitations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Pharmacological Efficacy of Probiotics in Respiratory Viral Infections: A Comprehensive Review.
- Author
-
Wahab, Shadma, Almaghaslah, Dalia, Mahmood, Syed Esam, Ahmad, Md Faruque, Alsayegh, Abdulrahman A., Abu Haddash, Yahya M., Rahman, Mohammad Akhlaquer, Ahamd, Irfan, Ahmad, Wasim, Khalid, Mohammad, Usmani, Shazia, Ahmad, Md Parwez, and Hani, Umme
- Subjects
- *
VIRUS diseases , *PROBIOTICS , *RESPIRATORY infections , *BACTERIAL diseases , *ANTIVIRAL agents , *MEDICAL research - Abstract
Mortality and morbidity from influenza and other respiratory viruses are significant causes of concern worldwide. Infections in the respiratory tract are often underappreciated because they tend to be mild and incapacitated. On the other hand, these infections are regarded as a common concern in clinical practice. Antibiotics are used to treat bacterial infections, albeit this is becoming more challenging since many of the more prevalent infection causes have acquired a wide range of antimicrobial resistance. Resistance to frontline treatment medications is constantly rising, necessitating the development of new antiviral agents. Probiotics are one of several medications explored to treat respiratory viral infection (RVI). As a result, certain probiotics effectively prevent gastrointestinal dysbiosis and decrease the likelihood of secondary infections. Various probiotic bacterias and their metabolites have shown immunomodulating and antiviral properties. Unfortunately, the mechanisms by which probiotics are effective in the fight against viral infections are sometimes unclear. This comprehensive review has addressed probiotic strains, dosage regimens, production procedures, delivery systems, and pre-clinical and clinical research. In particular, novel probiotics' fight against RVIs is the impetus for this study. Finally, this review may explore the potential of probiotic bacterias and their metabolites to treat RVIs. It is expected that probiotic-based antiviral research would be benefitted from this review's findings. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Clinical, Biological, and Radiological Findings and Management of Lower Respiratory Tract Infections in a Tertiary Hospital in Romania.
- Author
-
Bulata-Pop I, Stirbu I, Simionescu B, Grama A, and Junie LM
- Abstract
Background Lower respiratory tract infections (LRTIs) remain a significant concern in pediatrics due to their substantial burden among childhood diseases. Romania has recently attained the status of a high-income country. Even though the mortality rate from respiratory diseases has significantly declined from 24.1 per 100,000 individuals in 2000 to 5.3 per 100,000 in 2022, the rate remains notably higher than the European average. Diagnosing LRTI is challenging due to its clinical similarity to noninfectious respiratory illness and frequent false-positive results or incidental findings on microbiologic tests. This often leads to antimicrobial overuse and adverse outcomes. Additionally, antibiotic resistance poses a significant global public health threat. Patients and method We conducted a retrospective analysis of pediatric LRTI cases at a tertiary pediatric center in Romania to evaluate diagnostic testing, imaging use, etiology identification, and treatment approaches. Children under 18, admitted to the Emergency Clinical Hospital for Children in Cluj-Napoca during an eight-month peak respiratory season, were included. Data from electronic medical records were analyzed for demographics, symptoms, physical exams, laboratory data, presence of fever, etiology, treatment, and outcomes. Results In total, 222 children were included in this study, with a median age of 29 months. Among the participants, 58% were male. The average hospital stay was 11 days. The total number of cases was almost equally split between bronchiolitis and pneumonia, with lobar pneumonia accounting for 12% of the included patients. We found two statistically significant correlations between the presence of fever, intercostal retracting, and the subtype of LRTI. An inflammatory response defined as an elevated leucocyte count and elevated C-reactive protein (CRP) was more likely to appear in pneumonia cases than bronchiolitis. From a therapeutic point of view, the prescription of hydrocortisone was statistically linked to bronchiolitis, but its use did not shorten hospitalization time. Conclusion Policy interventions and targeted treatments can reduce LRTI incidence and improve outcomes. Based on our correlations between specific clinical traits and subtypes of LRTIs, the use of assessment scores in children helps predict severe illness and the need for hospitalization. Promoting hygiene, social distancing, and addressing socioeconomic factors are crucial. Larger sample sizes and advanced diagnostics are needed to refine treatment strategies further. Early antibiotic use in children has long-term health implications, including a higher risk of respiratory-caused premature death in adulthood. This emphasizes the need for improved diagnostic processes and specific etiological identification, with metagenomics showing promise in this area., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Bulata-Pop et al.)
- Published
- 2024
- Full Text
- View/download PDF
42. DYNAMICS OF CHILDHOOD RESPIRATORY INFECTIONS DURING THE COVID-19 PANDEMIC: THE EFFECT OF QUARANTINE АND BEYOND
- Author
-
Snezhina Lazova and Tsvetelina Velikova
- Subjects
covid-19 ,sars-cov-2 ,hypothesis ,respiratory viral infections ,influenza ,rsv ,rhinovirus ,children ,Medical philosophy. Medical ethics ,R723-726 - Abstract
Monitoring epidemic processes and the dynamics of the spread of infectious diseases is essential for predicting their distribution and effective planning in healthcare. The importance of studying seasonal trends in the spread of respiratory viral infections and the specific effects of non-pharmaceutical interventions in nationwide scales and the use of available vaccines stand out even more in the context of the coronavirus disease-19 (COVID-19) pandemic. Even if the dynamics of pediatric respiratory viral infections show some variation at the national and local levels, depending on health regulation, respiratory viral pathogens follow a typical pattern of incidence. Therefore, we hypothesize that anticipated reduction of the incidence of common respiratory viral infections would undoubtedly exert positive effects, such as ease of burdening healthcare that combates the COVID-19 pandemic. However, we suspect a shift in familiar seasonal characteristics of common respiratory viral infections. We also speculate that strict long-term limitations of the natural spread of respiratory viral infections can lead to the development of hard-to-predict epidemiological outliers. Additionally, the tricky balance between humanity’s natural impulse to return to normalcy and control the new and still dynamically evolving infection could lead to new threats from old and well-known pathogens. Finally, we hypothesize that the absence of regular influenza virus circulation may lead to a high mismatch rate and a significant reduction in flu vaccine efficacy.
- Published
- 2021
- Full Text
- View/download PDF
43. Environmental Impacts on COVID-19: Mechanisms of Increased Susceptibility
- Author
-
Stephania A Cormier, Ayaho Yamamoto, Kirsty R. Short, Luan Vu, and William A Suk
- Subjects
covid 19 ,air pollution ,respiratory viral infections ,age ,Infectious and parasitic diseases ,RC109-216 ,Public aspects of medicine ,RA1-1270 - Abstract
Background: Since 2019, severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) has resulted in >554M cases and >6.3M deaths worldwide. The disease caused by SARS-CoV-2, COVID-19, has resulted in a broad range of clinical symptoms differing in severity. Initially, the elderly were identified as particularly susceptible to severe COVID-19, with children experiencing less severe disease. However, as new variants arise, the epidemiology of SARS-CoV-2 infection is changing, and the disease severity in children is increasing. While environmental impacts on COVID-19 have been described, the underlying mechanisms are poorly described. Objective: The Pacific Basin Consortium for Environment and Health (PBC) held meeting on September 16, 2021, to explore environmental impacts on infectious diseases, including COVID-19. Methods: The PBC is an international group of environmental scientists and those interested in health outcomes. The PBC met to present preliminary data and discuss the role of exposures to airborne pollutants in enhancing susceptibility to and severity of respiratory tract viral infections, including COVID-19. Findings: Analysis of the literature and data presented identified age as an important factor in vulnerability to air pollution and enhanced COVID-19 susceptibility and severity. Mechanisms involved in increasing severity of COVID-19 were discussed, and gaps in knowledge were identified. Conclusions: Exposure to particulate matter (PM) pollution enhanced morbidity and mortality to COVID-19 in a pediatric population associated with induction of oxidative stress. In addition, free radicals present on PM can induce rapid changes in the viral genome that can lead to vaccine escape, altered host susceptibility, and viral pathogenicity. Nutritional antioxidant supplements have been shown to reduce the severity of viral infections, inhibit the inflammatory cytokine storm, and boost host immunity and may be of benefit in combating COVID-19.
- Published
- 2022
- Full Text
- View/download PDF
44. Editorial: Human coronavirus research: 20 years since the SARS-CoV outbreak
- Author
-
Burtram C. Fielding
- Subjects
severe acute respiratory syndrome (SARS-CoV) ,Middle East respiratory syndrome (MERS-CoV) ,SARS-CoV-2 (COVID-19) ,human coronavirus (HCoV) ,respiratory viral infections ,Microbiology ,QR1-502 - Published
- 2022
- Full Text
- View/download PDF
45. Repositioned Natural Compounds and Nanoformulations: A Promising Combination to Counteract Cell Damage and Inflammation in Respiratory Viral Infections
- Author
-
Alessia Mariano, Irene Bigioni, Magda Marchetti, Anna Scotto d’Abusco, and Fabiana Superti
- Subjects
natural compounds ,respiratory viral infections ,nanotechnology ,inflammation ,cell damage ,Organic chemistry ,QD241-441 - Abstract
Respiratory viral diseases are among the most important causes of disability, morbidity, and death worldwide. Due to the limited efficacy or side effects of many current therapies and the increase in antiviral-resistant viral strains, the need to find new compounds to counteract these infections is growing. Since the development of new drugs is a time-consuming and expensive process, numerous studies have focused on the reuse of commercially available compounds, such as natural molecules with therapeutic properties. This phenomenon is generally called drug repurposing or repositioning and represents a valid emerging strategy in the drug discovery field. Unfortunately, the use of natural compounds in therapy has some limitations, due to their poor kinetic performance and consequently reduced therapeutic effect. The advent of nanotechnology in biomedicine has allowed this limitation to be overcome, showing that natural compounds in nanoform may represent a promising strategy against respiratory viral infections. In this narrative review, the beneficial effects of some promising natural molecules, curcumin, resveratrol, quercetin, and vitamin C, which have been already studied both in native form and in nanoform, against respiratory viral infections are presented and discussed. The review focuses on the ability of these natural compounds, analyzed in in vitro and in vivo studies, to counteract inflammation and cellular damage induced by viral infection and provide scientific evidence of the benefits of nanoformulations in increasing the therapeutic potential of these molecules.
- Published
- 2023
- Full Text
- View/download PDF
46. The role of respiratory microbiota in the protection against viral diseases: respiratory commensal bacteria as next-generation probiotics for COVID-19.
- Author
-
ANDRADE, Bruno G. N., CUADRAT, Rafael R. C., TONETTI, Fernanda Raya, Haruki KITAZAWA, and VILLENA, Julio
- Subjects
COVID-19 ,VIRUS diseases ,INFLUENZA A virus ,SARS-CoV-2 ,COVID-19 pandemic ,RESPIRATORY diseases ,RESPIRATORY syncytial virus ,SCIENTIFIC knowledge - Abstract
On March 11, 2020, the World Health Organization declared a pandemic of coronavirus infectious disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and imposed the biggest public health challenge for our civilization, with unforeseen impacts in the subsequent years. Similar to other respiratory infections, COVID-19 is associated with significant changes in the composition of the upper respiratory tract microbiome. Studies have pointed to a significant reduction of diversity and richness of the respiratory microbiota in COVID-19 patients. Furthermore, it has been suggested that Prevotella, Staphylococcus, and Streptococcus are associated with severe COVID-19 cases, while Dolosigranulum and Corynebacterium are significantly more abundant in asymptomatic subjects or with mild disease. These results have stimulated the search for new microorganisms from the respiratory microbiota with probiotic properties that could alleviate symptoms and even help in the fight against COVID-19. To date, the potential positive effects of probiotics in the context of SARS-CoV-2 infection and COVID-19 pandemics have been extrapolated from studies carried out with other viral pathogens, such as influenza virus and respiratory syncytial virus. However, scientific evidence has started to emerge demonstrating the capacity of immunomodulatory bacteria to beneficially influence the resistance against SARS-CoV-2 infection. Here we review the scientific knowledge regarding the role of the respiratory microbiota in viral infections in general and in the infection caused by SARS-CoV-2 in particular. In addition, the scientific work that supports the use of immunomodulatory probiotic microorganisms as beneficial tools to reduce the severity of respiratory viral infections is also reviewed. In particular, our recent studies that evaluated the role of immunomodulatory Dolosigranulum pigrum strains in the context of SARS-CoV-2 infection are highlighted. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. Zinc and Respiratory Viral Infections: Important Trace Element in Anti-viral Response and Immune Regulation.
- Author
-
Sadeghsoltani, Fatemeh, Mohammadzadeh, Iraj, Safari, Mir-Meghdad, Hassanpour, Parisa, Izadpanah, Melika, Qujeq, Durdi, Moein, Soheila, and Vaghari-Tabari, Mostafa
- Abstract
Influenza viruses, respiratory syncytial virus (RSV), and SARS-COV2 are among the most dangerous respiratory viruses. Zinc is one of the essential micronutrients and is very important in the immune system. The aim of this narrative review is to review the most interesting findings about the importance of zinc in the anti-viral immune response in the respiratory tract and defense against influenza, RSV, and SARS-COV2 infections. The most interesting findings on the role of zinc in regulating immunity in the respiratory tract and the relationship between zinc and acute respiratory distress syndrome (ARDS) are reviewed, as well. Besides, current findings regarding the relationship between zinc and the effectiveness of respiratory viruses' vaccines are reviewed. The results of reviewed studies have shown that zinc and some zinc-dependent proteins are involved in anti-viral defense and immune regulation in the respiratory tract. It seems that zinc can reduce the viral titer following influenza infection. Zinc may reduce RSV burden in the lungs. Zinc can be effective in reducing the duration of viral pneumonia symptoms. Zinc may enhance the effectiveness of hydroxychloroquine in reducing mortality rate in COVID-19 patients. Besides, zinc has a positive effect in preventing ARDS and ventilator-induced lung damage. The relationship between zinc levels and the effectiveness of respiratory viruses' vaccines, especially influenza vaccines, is still unclear, and the findings are somewhat contradictory. In conclusion, zinc has anti-viral properties and is important in defending against respiratory viral infections and regulating the immune response in the respiratory tract. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
48. Hospital Visitors' Awareness and Adaptation of Preventive Measures for Middle East Respiratory Syndrome Coronavirus.
- Author
-
Aljarallah, Khalid M., Alrukban, Mohammed O., Alghamdi, Yazeed S., Alanazi, Bandar S., Alturki, Khaled E., Alkhunayfir, Hamad A., Alshammari, Madloul J., Alamri, Fahad M., and Hamadi, Hanadi Y.
- Subjects
SARS disease ,VISITATION in hospitals - Abstract
Objective: This study aims to assess the knowledge and awareness, and to identify the practice reflection of knowledge concerning Middle East Respiratory Syndrome (MERS) on hospital visitor's daily life. Methods: A cross-sectional study, conducted in 2 tertiary referral hospitals in Riyadh Saudi Arabia, from February 2015 to February 2016. A total random sample of 305 hospital visitors consented to participate. Data were collected through a self-administered questionnaire consisting of questions regarding awareness and practice of measures to prevent the spread of infection. Results: Study showed that participants have a fair knowledge regarding the cause of MERS (N = 228; 74.8%). Nearly half of them (47%) stated that camels are the source of the spread of MERS. Approximately 70% of the participants preferred both sanitization and wearing facemasks as preventive measures for MERS. However, only 3.95% practiced not eating camel products, such as milk and meat. Conclusions: Although hospital visitors showed some knowledge and positive awareness in several aspects of MERS awareness, there are weak areas where knowledge and awareness were not up to recommended guidelines. Continued educational programs are needed to improve awareness and knowledge of all the public toward MERS-coronavirus infection. This study may assist in the development of future strategies on preventive measures of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
49. Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components.
- Author
-
Li, Dan, Wang, Xianzheng, Liao, Yingzhao, Wang, Shouchuan, Shan, Jinjun, and Ji, Jianjian
- Subjects
PULMONARY surfactant ,MECONIUM aspiration syndrome ,COVID-19 ,COVID-19 treatment ,VIRUS diseases ,RESPIRATORY diseases - Abstract
Pulmonary surfactant constitutes an important barrier that pathogens must cross to gain access to the rest of the organism via the respiratory surface. The presence of pulmonary surfactant prevents the dissemination of pathogens, modulates immune responses, and optimizes lung biophysical activity. Thus, the application of pulmonary surfactant for the treatment of respiratory diseases provides an effective strategy. Currently, several clinical trials are investigating the use of surfactant preparations to treat patients with coronavirus disease 2019 (COVID-19). Some factors have been considered in the application of pulmonary surfactant for the treatment COVID-19, such as mechanical ventilation strategy, timing of treatment, dose delivered, method of delivery, and preparation utilized. This review supplements this list with two additional factors: accurate measurement of surfactants in patients and proper selection of pulmonary surfactant components. This review provides a reference for ongoing exogenous surfactant trials involving patients with COVID-19 and provides insight for the development of surfactant preparations for the treatment of viral respiratory infections. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
50. Epidemiological and clinical characteristics of respiratory viruses in 4403 pediatric patients from multiple hospitals in Guangdong, China
- Author
-
Yajie Zhang, Lin Qiao, Jinxiu Yao, Nan Yu, Xiaoping Mu, Shengqi Huang, Bo Hu, Weixuan Li, Feng Qiu, Fangyin Zeng, Cong Chen, Yuqiu Zhou, Bashan Zhang, Tian Cai, Weijia Wang, Xianjin Wu, Yiwen Zhou, Guochang Wang, Bo Situ, Shuling Lan, Na Li, Xiu Li, Zihua Li, Xin Li, Congrong Wang, Chao Yang, Pingfeng Feng, Hongxia Wang, Sijing Zhu, Yufeng Xiong, Min Luo, Wenjuan Shen, Xiumei Hu, and Lei Zheng
- Subjects
Acute respiratory infections ,Prevalence ,Seasonal ,Respiratory viral infections ,Multi-center ,China ,Pediatrics ,RJ1-570 - Abstract
Abstract Background Acute respiratory infections (ARI) cause considerable morbidity and mortality worldwide, especially in children. Unfortunately, there are limited multi-center data on common viral respiratory infections in south China. Methods A total of 4403 nasal swabs were collected from children in 10 cities in Guangdong, China in 2019. Seven respiratory viruses, influenza A virus (IFA), influenza B virus (IFB), respiratory syncytial virus (RSV), adenoviruses (ADV) and parainfluenza virus types 1–3 (PIV1, PIV2 and PIV3), were detected by direct immunofluorescence antibody assay. The personal information and clinical characteristics were recorded and analyzed. Results The results showed that at least one virus was detected in 1099 (24.96 %) samples. The detection rates of RSV, IFA, ADV, PIV3, PIV1 and PIV2 were 7.13 % (314/4403), 5.31 % (234/4403), 4.02 % (177/4403), 3.04 % (134/4403), 1.70 % (75/4403) and 1.16 % (51/4403), respectively. The detection rate of RSV was highest in 0–6-month-old children at 18.18 % (106/583), while the detection rate of IFA was highest in 12–18-year-old children at 20.48 % (17/83). The total detection rates in winter and spring were 35.67 % (219/614) and 34.56 % (403/1166), higher than those in summer, 17.41 % (284/1631), and autumn, 19.46 % (193/992). Conclusions RSV and IFA were the main respiratory viruses in children. With increasing age the detection rate of RSV decreased in children, but the trends for the detection rates of IFA and IFB were the opposite. This study provided the viral etiology and epidemiology of pediatric patients with ARI in Guangdong, China.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.